CW-3308
CW-3308 is an orally effective PROTAC that selectively targets BRD9 and is expected to be used to inhibit synovial sarcoma, rhabdomyoma, and other BRD9-dependent human diseases. CW-3308 is composed of PROTAC target protein ligand Naphthyridin-Me-dimethoxybenzene-COOH (red part), Linker 3-Azaspiro[5.5]undecane-9-methanol (HY-159598) (black part), E3 ubiquitin ligase ligand Thalidomide-methylpyrrolidine (HY-159597) (blue part), where the conjugate of E3 ubiquitin ligase ligand + linker is Thalidomide-pyrrolidine-C-azaspiro (HY-159599).
Product Specifications
CAS Number
3055592-99-6
UNSPSC
12352005
Target
Epigenetic Reader Domain; PROTACs
Type
Reference compound
Related Pathways
Epigenetics; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cw-3308.html
Purity
99.54
Solubility
DMSO : 4.17 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=C4C(CN(CC(CC5)CCC65CCN(C(C7=C(OC)C=C(C(C8=CC=NC=C98)=CN(CC)C9=O)C=C7OC)=O)CC6)C4)=C3)=O
Molecular Formula
C45H48N6O8
Molecular Weight
800.90
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Phospho-Tau (Ser262) Polyclonal Antibody, AbBy Fluor™ 750 Conjugated
SARS-CoV-2 NSP13/Helicase/SARS Rabbit Polyclonal Antibody
